



AMARIN TO PRESENT AT CANACCORD GENUITY GLOBAL GROWTH CONFERENCE

Dublin, Ireland and Mystic, CT, USA , July 29, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the 30th Annual Canaccord Genuity Global Growth Conference on Thursday, August 12, 2010 at 1:30pm (EDT). This conference will be held at the InterContinental Boston in Boston, Massachusetts.

A live audio webcast of the presentation will be available at the following URL:

<http://www.wsw.com/webcast/canaccord2/amrn/>

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two pivotal Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit

www.amarincorp.com.

Contacts:

Investor Contact Information:

John F. Thero

Chief Financial Officer

In US: +1 (860) 572 4979

investor.relations@amarincorp.com

Lee M. Stern

The Trout Group

In U.S. +1 (646) 378-2922

lstern@troutgroup.com

International Media Contact Information:

Mark Swallow or David Dible

Citigate Dewe Rogerson

In UK: +44 (0)207 638 9571

mark.swallow@citigatedr.co.uk